Reardon Andrew
Ligand Pharmaceuticals Incorporated - Common Stock · CLO & Secretary
Reardon Andrew is listed in filings as CLO & Secretary at Ligand Pharmaceuticals Incorporated - Common Stock. This profile follows SEC Form 4 activity through Jun 2, 2026, including sale activity. Recent filings connect the profile to Ligand Pharmaceuticals Incorporated - Common Stock (LGND). The current snapshot covers public activity from Jul 2, 2024 to Jun 2, 2026. Reported amounts are shown as $323.6K to $261.4K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.